Monday, May 15, 2017

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing nitty-gritty attacks, blood clots or extirpation than the par lower dose in patients who had received artery-opening stents, unfamiliar research shows. The higher dose - facsimile the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to answer to the drug at lower doses recommended site. Plavix (clopidogrel) helps prevent clots from forming in patients who have ribald platelet reactivity and who have had stents inserted to prop open blocked arteries.

But the redone study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to go into lead author Dr Matthew Price, who presented the findings Tuesday at the annual conclave of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to favour heart patients who don't respond well to Plavix? "It remains random to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn vimax pill in manila. "It's an foremost study to have done but the key issues are that a significant proportion of the patients remained with excited platelet reactivity even after being on the higher dose".

Previous, smaller studies had indicated that Plavix might have more of an effect if the dispense was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a exalted reactivity informed is associated with poorer outcomes after angioplasty and/or stenting. But until now, a precipitous rise in the dose of Plavix "has not been tested in a large randomized clinical trial".

For this trial, investigators tested a broad group of patients for platelet reactivity after they had undergone angioplasty to district a drug-eluting stent. Drug-eluting stents emit medicines that help section off vessel re-closure. Over 2200 patients with high platelet reactivity were then randomized to make 150 milligrams a day of Plavix or the standard 75-milligram dose.

After six months, 2,3 percent of those taking either the higher or the turn down dose suffered heart attacks, experienced blood clots in their stents, or died, the researchers report. Those taking the higher dosage of the blood-thinner didn't have any worse bleeding than those taking the prevalent dose, indicating that the higher dose of Plavix in this group of patients wasn't any less safe. The chew over was sponsored by Accumetrics, which makes VerifyNow, a test used to limitation platelet function.

The makers of Plavix, Sanofi-Aventis and Bristol-Myers Squibb provided the drug, and be conducive to investigator Price also disclosed ties with pharmaceutical companies. "The trial does not support a therapy strategy of high dose clopidogrel in - patients with high-risk reactivity identified by a unmarried platelet test". Still, Prasad said that higher risk patient populations may distress to be studied before drawing any firm conclusions about dosing provillusshop com. "Or maybe we need a more potent drug".

No comments:

Post a Comment